(May 20, 2024, 2:24 PM EDT) -- WASHINGTON, D.C. — Two flavored e-liquid companies filed a brief with the U.S. Supreme Court on May 17 opposing the Food and Drug Administration’s petition for a writ of certiorari challenging the en banc Fifth Circuit U.S. Court of Appeals’ reversal of FDA’s ban of their products as “arbitrary,” writing that the ruling does not require review when other pending e-cigarette petitions for certiorari present better vehicles to review circuit splits on the topic....